The successful use of umbilical cord blood in clinical applications depends heavily on rigorous evaluation of its viability and integrity after collection. Professionals in the field must navigate a series of complex procedures to ensure that the potent stem cells preserved in the blood remain functional for future therapeutic use. This article outlines the critical steps and cutting-edge techniques involved in testing cord blood viability, from initial processing through advanced laboratory assays and stringent quality control measures.
Collection and Initial Processing
Umbilical cord blood procurement begins immediately after birth, when the placenta and cord are clamped and the blood is collected via gravity drainage or gentle aspiration. At this stage, adherence to standardized protocols is paramount to minimize contamination and preserve the cellular composition.
Key Considerations During Collection
- Sterile Technique: Medical staff must use aseptic methods to prevent microbial intrusion.
- Anticoagulant Addition: Popular formulations include citrate-phosphate-dextrose (CPD) to prevent clotting while maintaining cell integrity.
- Volume Measurement: Accurate documentation of collected volume helps estimate cell yield and feasibility for banking.
Transportation and Temperature Control
Once collected, the bag of cord blood should be kept between 4°C and 24°C. Rapid transport to the processing laboratory—ideally within 24 hours—is essential to maintain viability of hematopoietic cells and limit the risk of cell death due to thermal fluctuations.
Laboratory Assessment Methods
After arrival at the processing facility, cord blood units undergo several analytical procedures designed to quantify and verify the functional capacity of the stem cells before cryopreservation.
Cell Counting and Viability Assays
Automated hematology analyzers provide an initial total nucleated cell (TNC) count. However, to accurately gauge viability, laboratories employ assays such as:
- Trypan Blue Exclusion Test – A dye uptake method that differentiates live from dead cells.
- Pros: Rapid and cost-effective.
- Cons: Subjective manual counting can introduce variability.
- Flow Cytometry with 7-AAD or PI Staining – Dead cells incorporate the dye, allowing precise quantification of viable versus non-viable cells.
- Fluorometric ATP Assays – Measurement of intracellular ATP, correlating with metabolic activity and potency.
CD34+ Enumeration
Enumeration of CD34+ progenitor cells via immunophenotyping is a critical parameter. The concentration of CD34+ cells often correlates with engraftment success in transplant recipients.
Microbial Screening
To prevent transfusion-associated infections, samples are cultured to detect bacterial or fungal contaminants. Positive cultures necessitate quarantine and possible discard of the unit, underscoring the importance of strict aseptic collection.
Quality Control and Regulatory Standards
Ensuring consistent quality control across multiple cord blood banks requires harmonized protocols aligned with international guidelines, such as those from the Foundation for the Accreditation of Cellular Therapy (FACT) and the AABB.
Establishing Acceptance Criteria
Each cord blood unit must meet predefined thresholds for key parameters:
- Total Nucleated Cell Count ≥ 1.0 x 109
- CD34+ Cells ≥ 2.0 x 106
- Post-thaw Viability ≥ 70% as measured by flow cytometry
- Negative Sterility Cultures at 14 days
Documentation and Traceability
A robust chain-of-custody system tracks each cord blood unit from collection to final release, documenting all processing steps and test results. Electronic records help facilitate audits and regulatory inspections.
Cryopreservation Protocols
Cryoprotectant agents, such as dimethyl sulfoxide (DMSO), are added to prevent ice crystal formation during freezing. Controlled-rate freezers cool samples at approximately –1°C per minute until reaching –150°C, after which units are transferred to liquid nitrogen storage.
Future Directions in Cord Blood Viability Testing
Innovations continue to refine the evaluation of cord blood units, with a focus on optimizing recovery rates, reducing assay time, and improving predictive power of testing methods.
Advanced Imaging and Functional Assays
High-content imaging platforms enable real-time analysis of cell morphology and proliferation, offering a non-destructive alternative to traditional assays. Colony-forming unit (CFU) assays remain the gold standard for assessing hematopoietic lineage potential, though new microfluidic systems promise faster turnaround.
Genomic and Proteomic Profiling
Next-generation sequencing and mass spectrometry can uncover subtle molecular signatures indicative of long-term engraftment potential. Integrating omics data with conventional viability metrics may enhance selection of superior units for transplantation.
Automation and Standardization
The implementation of robotic sample handling and closed-system processing reduces human error and contamination risk. Collaborative efforts toward universally accepted protocols will further streamline regulatory approvals across regions.
Ensuring the viability of cord blood units demands meticulous attention to every step, from collection through cryostorage. By adopting advanced viability testing techniques and upholding rigorous standardized procedures, cord blood banks can offer families the highest confidence in the therapeutic potential of preserved stem cells.